Search

Your search keyword '"Poddubnyy, D"' showing total 239 results

Search Constraints

Start Over You searched for: Author "Poddubnyy, D" Remove constraint Author: "Poddubnyy, D" Database Unpaywall Remove constraint Database: Unpaywall
239 results on '"Poddubnyy, D"'

Search Results

1. OP0085 CLINICAL FEATURES OF PATIENTS WITH SpA, WITH OR WITHOUT IBD: RESULTS FROM THE METEOR COHORT

3. POS0249 ASSOCIATIONS BETWEEN CLINICAL CHARACTERISTICS AND SCREENING MRI FINDINGS: EXPLORATORY ANALYSIS OF THE ONGOING PHASE 4, MULTICENTER, RANDOMIZED, CONTROLLED STAR STUDY OF BIOLOGIC-NAÏVE PATIENTS WITH PsA WITH MRI-CONFIRMED AXIAL INVOLVEMENT

7. LBA0003 MINIMAL SPINAL RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS OVER 2 YEARS OF BIMEKIZUMAB TREATMENT: RESULTS FROM A PHASE 3 OPEN-LABEL EXTENSION STUDY

8. POS0050 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 2-YEAR DATA FROM THE PHASE 3 SELECT-AXIS 2 STUDY

10. POS0194 FACTORS ASSOCIATED WITH RADIOGRAPHIC SPINAL PROGRESSION IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS RECEIVING IL-17A INHIBITOR OR TNF INHIBITOR THERAPY: A POST-HOC ANALYSIS OF THE SURPASS STUDY

11. POS0215 LONG-TERM SAFETY AND EFFICACY OF BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 5-YEAR RESULTS FROM A PHASE 2B STUDY AND ITS OPEN-LABEL EXTENSION

13. AB0881 LONG-TERM SAFETY AND TOLERABILITY OF BIMEKIZUMAB IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS: RESULTS FROM POOLED PHASE 2B/3 STUDIES

14. POS0058 IMPACT OF BIMEKIZUMAB ON MRI INFLAMMATORY AND STRUCTURAL LESIONS IN THE SACROILIAC JOINTS OF PATIENTS WITH AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS AND POST HOC ANALYSES FROM THE BE MOBILE 1 AND 2 PHASE 3 STUDIES

19. Résolution des enthésites et des arthrites périphériques avec le bimékizumab chez les patients atteints de spondyloarthrite axiale : résultats à la semaine 52 des études de phase III BE MOBILE 1 et BE MOBILE 2

20. Tolérance et efficacité à long terme du bimékizumab chez les patients atteints de spondylarthrite ankylosante active : résultats à 5 ans d’une étude de phase IIb et de son extension en ouvert

21. Effet du sécukinumab versus adalimumab biosimilaire sur la progression radiographique chez les patients atteints de spondyloarthrite axiale radiographique : analyse en sous-groupes avec sur le statut syndesmophytes et protéine C-réactive à l’inclusion

22. Le bimékizumab réduit les lésions inflammatoires à l’IRM chez les patients atteints de spondyloarthrite axiale : résultats à la semaine 52 des études de phase III BE MOBILE 1 et 2

23. Tolérance à long terme du bimékizumab chez les patients atteints de spondyloarthrite axiale (axSpA) et de rhumatisme psoriasique (RhPso) : résultats groupés des études de phase IIb/III

24. Effet du sécukinumab versus adalimumab biosimilaire sur la progression radiographique chez les patients atteints de spondyloarthrite axiale radiographique : étude randomisée de phase 3b

25. POS0246 BIMEKIZUMAB REDUCED MRI INFLAMMATORY LESIONS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: WEEK 52 RESULTS FROM THE BE MOBILE 1 AND BE MOBILE 2 PHASE 3 STUDIES

28. AB1010 WHICH FACTORS ARE ASSOCIATED WITH CLINICALLY HIGH DISEASE ACTIVITY IN AXIAL SPONDYLOARTHRITIS? RESULTS FROM THE INTERNATIONAL MAP OF AXIAL SPONDYLOARTHRITIS (IMAS)

29. POS0299 NEUROPATHIC AND NEUROPLASTIC PAIN COMPONENTS DETERMINE THE PRESENCE OF RESIDUAL SYMPTOMS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS RECEIVING BIOLOGICAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS

30. AB0093 COMPLEMENT IN THE DIAGNOSIS OF AXIAL SPONDYLOARTHRITIS (AXSPA). INVESTIGATIONS IN A CROSS-SECTIONAL COHORT (OPTIREF) OF PATIENTS SUSPECTED OF AXIAL SPONDYLOARTHRITIS

31. OP0187 REGIONAL DIFFERENCES IN CLINICAL PHENOTYPE OF AXIAL SPONDYLOARTHRITIS. RESULTS FROM THE INTERNATIONAL MAP OF AXIAL SPONDYLOARTHRITIS (IMAS)

33. POS0878 SCREENING FOR THE EARLY IDENTIFICATION OF PSORIATIC ARTHRITIS WITH AXIAL INVOLVEMENT (AXPSA) IN A COHORT OF ITALIAN PATIENTS AFFECTED BY PSORIASIS: RESULTS OF A DERMO-RHEUMATOLOGIC CROSS-SECTIONAL STUDY (ATTRACT)

35. POS0689 DIAGNOSTIC DELAY IN PATIENTS INCLUDED IN THE INTERNATIONAL MAP OF AXIAL SPONDYLOARTHRTIS: ASSOCIATIONS WITH GEOGRAPHIC, SOCIO-DEMOGRAPHIC AND DISEASE-RELATED FACTORS

36. AB0987 FEMALES WITH AXIAL SPONDYLOARTHRITIS REPORT HIGHER BURDEN OF DISEASE AND WORSE PATIENT-REPORTED OUTCOMES. RESULTS FROM THE INTERNATIONAL MAP OF AXIAL SPONDYLOARTHRITIS (IMAS)

37. POS0250 PLACEBO-CONTROLLED EFFICACY AND SAFETY OF UPADACITINIB THROUGH ONE YEAR IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS

38. POS0429 THE COMPLEMENT SYSTEM AND RESPONSE TO TNF INHIBITION IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS. POST HOC ANALYSIS FROM CONSUL, A LONGITUDINAL MULTI-CENTER RCT COHORT OF R-AXSPA-PATIENTS WITH A HIGH RISK OF STRUCTURAL PROGRESSION INITIATING TREATMENT WITH TNF-INHIBITOR

39. OP0059 EFFECT OF SECUKINUMAB VERSUS ADALIMUMAB BIOSIMILAR ON RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: A RANDOMISED PHASE IIIB STUDY

40. POS0043 COMPLEMENT IN RADIOGRAPHIC AXSPA – BIOMARKERS OF RADIOGRAPHIC PROGRESSION? POST HOC ANALYSIS FROM CONSUL, A LONGITUDINAL MULTI-CENTER RANDOMIZED CONTROLLED TRIAL COHORT OF AXSPA-PATIENTS WITH A HIGH RISK OF STRUCTURAL PROGRESSION INITIATING TREATMENT WITH TNF-I

43. POS0298 THE INTERNATIONAL MAP OF AXIAL SPONDYLOARTHRITIS (IMAS). RESULTS FROM THE PERSPECTIVE OF 5,557 PATIENTS FROM 27 COUNTRIES AROUND THE WORLD

44. AB0938 SAFETY PROFILE OF BIMEKIZUMAB AT WEEK 16 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS: RESULTS FROM FOUR PLACEBO-CONTROLLED PHASE 3 STUDIES

45. OP0055 ASAS CONSENSUS DEFINITION OF EARLY AXIAL SPONDYLOARTHRITIS

47. OP0061 DEVELOPMENT OF EXTRA-MUSCULOSKELETAL MANIFESTATIONS IN UPADACITINIB-TREATED PATIENTS WITH PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS, OR NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS

48. Amélioration des signes et symptômes chez des patients atteints de spondyloarthrite axiale radiographique traités par bimékizumab : résultats à 24 semaines d’une étude de phase III, multicentrique, randomisée et contrôlée par placebo

49. Efficacité d’upadacitinib chez des patients atteints de spondyloarthrite axiale non radiographique en fonction des signes objectifs d’inflammation à l’inclusion

50. Profil de tolérance de l’ixékizumab dans le traitement du rhumatisme psoriasique et de la spondyloarthrite axiale jusqu’à 3 ans : mise à jour d’une analyse intégrée de tolérance

Catalog

Books, media, physical & digital resources